Radiotherapy and immune checkpoints inhibitors for advanced melanoma

Radiotherapy and Oncology

Volumn 120, Issue 1, 2016, Pages 1-12

  Filippi, Andrea Riccardo ^a   Fava, Paolo ^a   Badellino, Serena ^a   Astrua, Chiara ^a   Ricardi, Umberto ^a   Quaglino, Pietro ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Immunotherapy; Melanoma; Radiotherapy; Stereotactic radiotherapy

Indexed keywords

DACARBAZINE; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COLITIS; DIARRHEA; HEPATITIS; HUMAN; HYPOPHYSITIS; META ANALYSIS; METASTATIC MELANOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); IMMUNOTHERAPY; MELANOMA; PROSPECTIVE STUDY;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; PROGRAMMED CELL DEATH 1 RECEPTOR; PROSPECTIVE STUDIES;

EID: 84992021239     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2016.06.003     Document Type: Review

References (87)

1. [1] Vesely, M.D., Kershaw, M.H., Schreiber, R.D., Smyth, M.J., Natural innate and adaptive immunity to cancer. Ann Rev Immunol 29 (2011), 235–271.
2. [2] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
3. [3] Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu Rev Immunol 22 (2004), 329–360.
4. [4] Schadendorf, D., Hodi, F.S., Robert, C., et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J Clin Oncol 33 (2015), 1889–1894.
5. [5] Davey, R.J., Westhuizen, A.V., Bowden, N.A., Metastatic melanoma treatment: combining old and new therapies. Crit Rev Oncol Hematol, 2015, 10.1016/j.critrevonc.2015.11.011 pii: S1040-8428(15)30080-9. [Epub ahead of print].
6. [6] Golden, E.B., Pelliciotta, I., Demaria, S., Barcellos-Hoff, M.H., Formenti, S.C., The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol, 2, 2012, 88.
7. [7] Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and RT. Nat Med 13 (2007), 1050–1059.
8. [8] Demaria, S., Pilones, K.A., Vanpouille-Box, C., Golden, E.B., Formenti, S.C., The optimal partnership of radiation and immunotherapy: from preclinical studies to clinical translation. Radiat Res 182 (2014), 170–181.
9. [9] Demaria, S., Ng, B., Devitt, M.L., et al. Ionizing radiation inhibition of distant untreated tumours (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58 (2004), 862–870.
10. [10] Kingsley, D.P., An interesting case of possible abscopal effect in malignant melanoma. Br J Radiol 48 (1975), 863–866.
11. [11] Demaria, S., Kawashima, N., Yang, A.M., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 11 (2005), 728–734.
12. [12] Postow, M.A., Callahan, M.K., Barker, C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366 (2012), 925–931.
13. [13] Grimaldi, A.M., Simeone, E., Giannarelli, D., et al. Abscopal effects of RT on advanced melanoma patients who progressed after ipilimumab immunotherapy. Oncoimmunology, 2014, 1–8, e28780.
14. [14] Barker, C.A., Postow, M.A., Khan, S.A., et al. Concurrent RT and ipilimumab immunotherapy for patients with melanoma. Cancer Immunol Res 1 (2013), 92–98.
15. [15] Demaria, S., Pilones, K.A., Formenti, S., Dustin, M., Exploiting the stress response to radiation to sensitize poorly immunogenic tumours to anti-CLA-4 treatment. Oncoimmunology, 2, 2013, e23127.
16. [16] Twyman-Saint Victor, C., Rech, A.J., Maity, A., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520:7547 (2015), 373–377.
17. [17] Ricardi, U., Filippi, A.R., Franco, P., New concepts and insights into the role of radiation therapy in extracranial metastatic disease. Expert Rev Anticancer Ther 13 (2013), 1145–1155.
18. [18] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med, 151, 2009, W264.
19. [19] Baumann, M., Overgaard, J., What next?. Radiother Oncol 110 (2014), 1–2.
20. [20] Hamm, C., Verma, S., Petrella, T., Bak, K., Charette, M., Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat Rev 34 (2008), 145–156.
21. [21] Ives, N.J., Stowe, R.L., Lorigan, P., Wheatley, K., Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol 25 (2007), 5426–5434.
22. [22] Sasse, A.D., Sasse, E.C., Clark, L.G., Ulloa, L., Clark, O.A., Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev, 1, 2007 CD005413.
23. [23] Korn, E.L., Liu, P.Y., Lee, S.J., et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 26 (2008), 527–534.
24. [24] Pardoll, D.E., The blockade of immune checkpoints in cancer immunotherapy. Nat Rev 12 (2012), 252–264.
25. [25] Korman, A.J., Peggs, K.S., Allison, J.P., Checkpoints blockade in cancer immunotherapy. Adv Immunol 90 (2006), 297–339.
26. [26] Wolchok, J.D., Neyns, B., Linette, G., et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2 (2010), 155–164.
27. [27] Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363 (2010), 711–723.
28. [28] Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
29. [29] Ascierto, P.A., Simeone, E., Sileni, V.C., et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access program cohort. J Transl Med, 12, 2014, 116.
30. [30] Wolchok, J.D., Hoos, A., O'Day, S., et al. Guidelines for the evaluation of immune therapy activity in solid tumours: immune-related response criteria. Clin Cancer Res 15 (2009), 7412–7420.
31. [31] Ribas, A., Chmielowski, B., Glaspy, J.A., Do we need a different set of response assessment criteria for tumour immunotherapy?. Clin Cancer Res 15 (2009), 7116–7118.
32. [32] Brahmer, J.R., Drake, C.G., Wollner, I., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumours: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28 (2010), 3167–3175.
33. [33] Metcalfe, W., Anderson, J., Trinh, V.A., et al. Anti-programmed cell death-1 (PD-1) monoclonal antibodies in treating advanced melanoma. Discov Med 19 (2015), 393–401.
34. [34] Ganghadar, T.C., Vonderheide, R.H., Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol 11 (2014), 91–99.
35. [35] Robert, C., Long, G.V., Brady, B., et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372 (2014), 320–330.
36. [36] Weber, J., D'Angelo, S.P., Minor, D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 16 (2015), 375–384.
37. [37] Hamid, O., Robert, C., Daud, A., et al. Safety and tumour responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 369 (2013), 134–144.
38. [38] Ribas, A., Puzanov, I., Dummer, R., et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol 16 (2015), 908–918.
39. [39] Robert, C., Schachter, J., Long, G.V., et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372 (2015), 2521–2532.
40. [40] Wolchok, J.D., Kluger, H., Callahan, M.K., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369 (2013), 122–133.
41. [41] Postow, M.A., Chesney, J., Pavlick, A.C., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Eng J Med 372 (2015), 2006–2017.
42. [42] Larkin, J., Chiarion-Sileni, V., Gonzalez, R., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
43. [43] Hodi, F.S., Postow, M.A., Chesney, J.A., et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. Presented at American Society of Clinical Oncology Annual Meeting 2015. J Clin Oncol, 33, 2015, 9004.
44. [44] Hodi, F.S., Gibney, G., Sullivan, R., et al. An open-label, randomized, phase 2 study of nivolumab given sequentially with ipilimumab in patients with advanced melanoma (CheckMate 064). Presented at the European Cancer Conference (ECCO)-European Society of Medical Oncology (ESMO) Annual Meeting, 2015.
45. [45] Gajewski, T.F., Meng, Y., Blank, C., et al. Immune resistance orchestrated by the tumour microenvironment. Immunol Rev 213 (2006), 131–145.
46. [46] Smyth, M.J., Godfrey, D.I., Trpani, A.J., A fresh look at the tumour immunosurveillance and immunotherapy. Nat Immunol 2 (2001), 293–299.
47. [47] Demaria, S., Bhardwaj, N., McBride, W.H., Formenti, S.C., Combining RT and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 63 (2005), 655–666.
48. [48] Lugade, A.A., Moran, J.P., Gerber, S.A., Rose, R.C., Frelinger, J.G., Lord, E.M., Local radiation therapy of B16 melanoma tumours increases the generation of tumour antigen-specific effector cells that traffic to the tumour. J Immunol 174 (2005), 7516–7523.
49. [49] Reits, E.A., Hodge, J.W., Herberts, C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J Exp Med 203 (2006), 1259–1271.
50. [50] Lugade, A.A., Sorensen, E.W., Gerber, S.A., Moran, J.P., Frelinger, J.G., Lord, E.M., Radiation-induced IFN-gamma production within the tumour microenvironment influences antitumour immunity. J Immunol 180 (2008), 3132–3139.
51. [51] Meng, Y., Efimova, E.V., Hamzeh, K.W., et al. Radiation-inducible immunotherapy for cancer: senescent tumour cells as a cancer vaccine. Mol Ther 20 (2012), 1046–1055.
52. [52] Demaria, S., Golden, E.B., Formenti, S.C., Role of local RT in cancer immunotherapy. JAMA Oncol, 2015, 10.1001/jamaoncol.2015.2756 Published online August 13, 2015.
53. [53] Matsumura, S., Wang, B., Kawashima, N., Braunstein, S., Badura, M., Cameron, T.O., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 181 (2008), 3099–3107.
54. [54] Soto-Patoja, D.R., Terabe, M., Ghosh, A., et al. CD47 in the tumour microenvironment limits cooperation between anti-tumour T cell immunity and radiation therapy. Cancer Res 74 (2014), 6771–6783.
55. [55] Price, J.G., Idoyaga, J., Salmon, H., et al. CDKN1A regulates Langerhans cell survival and promotes T-reg cell generation upon exposure to ionizing irradiation. Nat Immunol 16 (2015), 1060–1068.
56. [56] Zitvogel, L., Kroemer, G., Subversion of anticancer immunosurveillance by RT. Nat Immunol 16 (2015), 1005–1007.
57. [57] Formenti, S.C., Demaria, S., Combining RT and cancer immunotherapy: a paradigm shift. J Natl Canc Inst 105 (2013), 256–265.
58. [58] Zegers, C.M., Rekers, N.H., Quaden, D.H., et al. RT combined with the immunocytokine L19-IL-2 provides long lasting antitumour effects. Clin Canc Res 21 (2015), 1151–1160.
59. [59] Rekers, N.H., Zegers, C.M., Yaromina, A., et al. Combination of RT with the immunocytokine L19-IL-2: additive effect in a NK cell dependent tumour model. Radiother Oncol 116 (2015), 438–442.
60. [60] Sharabi, A.B., Lim, M., DeWeese, T.L., Drake, C.G., Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16 (2015), e498–e509.
61. [61] Perez, C.A., Fu, A., Onishko, H., et al. Radiation induces an antitumour immune response to mouse melanoma. Int J Radiat Biol 85 (2009), 1126–1136.
62. [62] Lee, Y., Auh, S.L., Wang, Y., et al. Therapeutic effects of ablative radiation on local tumour require CD8fl T cells: Changing strategies for cancer treatment. Blood 114 (2009), 589–595.
63. [63] Sharabi, A.B., Nirschl, C.J., Kochel, C.M., et al. Stereotactic radiation therapy augments antigen-specific PD-1 mediated anti-tumour immune responses via cross-presentation of tumour antigen. Cancer Immunol Res 3 (2015), 345–355.
64. [64] Park, S.S., Dong, H., Liu, X., et al. PD-1 restrains RT-induced abscopal effect. Cancer Immunol Res 3 (2015), 610–619.
65. [65] Golden, E.B., Chhabra, A., Chachoua, A., et al. Local RT and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16 (2015), 795–803.
66. [66] Ngiow, S.F., McArthur, G.A., Smyth, M.J., RT complements immune checkpoint blockade. Cancer Cell 27 (2015), 437–438.
67. [67] Hiniker, S.M., Chen, D.S., Reddy, S., et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol 5 (2012), 404–407.
68. [68] Chandra, R.A., Wilhite, T.J., Balboni, T.A., et al. A systematic evaluation of abscopal responses following RT in metastatic melanoma patients treated with ipilimumab. Oncoimmunology, 4, 2015, e1046028.
69. [69] Stamell, E.F., Wolchock, J.D., Gnjatic, S., et al. The abscopal affect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85 (2013), 293–295.
70. [70] Barker, C.A., Postow, M.A., Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88 (2014), 986–997.
71. [71] Muller-Brenne, T., Rudolph, B., Schmidberger, H., Successful therapy of a cerebral metastasized malignant melanoma by whole-brain radiation therapy and ipilimumab. J Dtsch Dermatol Ges 9 (2003), 787–788.
72. [72] Bot, I., Blank, C.U., Brandsma, D., Clinical and radiological response of leptomeningeal melanoma after whole brain RT and ipilimumab. J Neurol 259 (2012), 1976–1978.
73. [73] Gerber, N.K., Young, R.J., Barker, C.A., et al. Ipilimumab and whole brain RT for melanoma brain metastases. J Neuroncol 121 (2015), 159–165.
74. [74] Schoenfeld, J.D., Mahadevan, A., Floyd, S.R., et al. Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. J Immunother Cancer, 3, 2015, 50.
75. [75] Silk, A.W., Bassetti, M.F., West, B.T., Tsien, C.I., Lao, C.D., Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2 (2013), 899–906.
76. [76] Knisely, J.P., Yu, J.B., Flanigan, J., et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117 (2012), 227–233.
77. [77] Mathew, M., Tam, M., Ott, P.A., et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23 (2013), 191–195.
78. [78] Tazi, K., Hataway, A., Chiuzan, C., Shirai, K., Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4 (2015), 1–6.
79. [79] Kiess, A.P., Wolchok, J.D., Barker, C.A., et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92 (2015), 368–375.
80. [80] Du-Four, S., Wilgenhof, S., Duerinck, J., et al. Radiation necrosis of the brain in melanoma patients successfully treated with ipilimumab: three case studies. Eur J Cancer 48 (2012), 3045–3051.
81. [81] Ricardi, U., Badellino, S., Filippi, A.R., Clinical applications of stereotactic radiation therapy for oligometastatic cancer patients: a disease-oriented approach. J Radiat Res, 2016 pii: rrw006.
82. [82] Dewan, M.Z., Galloway, A.E., Kawashima, N., et al. Fractionated but not single-dose RT induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Canc Res 15 (2009), 5379–5388.
83. [83] Golden, E.B., Demaria, S., Schiff, P.B., et al. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 1 (2013), 365–372.
84. [84] Fuks, Z., Kolesnik, R., Engaging the vascular component of the tumour response. Cancer Cell 8 (2005), 89–91.
85. [85] Reits, E.A., Hodge, J.W., Herberts, C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumour immunotherapy. J Exper Med 203 (2006), 1259–1271.
86. [86] Smilowitz, H.M., Micca, P.L., Sasso, D., et al. Increasing radiation dose improves immunotherapy outcome and prolongation of tumor dormancy in a subgroup of mice treated for advanced intracerebral melanoma. Cancer Immunol Immunother 65 (2016), 127–139.
87. [87] Golden, E.B., Formenti, S.C., Radiation therapy and immunotherapy: growing pains. Int J Radiat Oncol Biol Phys 91 (2015), 252–254.